98%
921
2 minutes
20
Obesity has emerged as a major global health issue. The ratio of male to female patients undergoing metabolic bariatric surgery (MBS) is 1:3.5. Although not as dramatic compared to the global trend, the rate of obesity in women of reproductive age in Korea has been steadily increasing over the past several decades. The impact of obesity on reproductive health and perinatal outcomes should be carefully considered when consulting female candidates of reproductive age for MBS. Obesity adversely affects reproductive health by causing menstrual irregularities, anovulation, subfertility, and increased miscarriage risk, as well as impairing the success of assisted reproductive technologies. Maternal obesity also heightens the risk of adverse perinatal outcomes, including childhood obesity and metabolic disorders. MBS has been shown to improve fertility outcomes and reduce obesity-related pregnancy complications, although concerns remain regarding potential risks such as small-for-gestational-age infants due to rapid weight loss and nutritional deficiencies. Despite these implications, current MBS guidelines rarely address the unique needs of reproductive-age women. In response, the Korean Society for Metabolic and Bariatric Surgery convened a task force to develop evidence-based recommendations tailored to this population. This position statement aims to guide the management of obesity in women of reproductive age to optimize reproductive and perinatal outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059304 | PMC |
http://dx.doi.org/10.17476/jmbs.2025.14.1.1 | DOI Listing |
Diabetes Res Clin Pract
September 2025
Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan. Electronic address:
Obes Surg
September 2025
Department of Medical and Surgical Sciences, Internal Medicine Unit, Columbus-Gemelli Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Obesity is a globally prevalent condition associated with elevated morbidity and mortality. Metabolic and bariatric surgery offers a definitive treatment for class III (BMI > 40) obesity, achieving substantial, enduring weight loss and improving metabolic health. Despite extensive research on the physical benefits, comparatively fewer reviews investigate the psychosocial and relational changes accompanying these procedures.
View Article and Find Full Text PDFObes Surg
September 2025
Monterrey Institute of Technology and Higher Education, Guadalajara, Mexico.
Cell Metab
August 2025
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong 250012, China; National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Sha
Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine disorder characterized by intertwined reproductive and metabolic abnormalities. While its causal origins remain incompletely understood, accumulating evidence suggests metabolic dysfunctions-manifested by insulin resistance, obesity, hyperglycemia, and dyslipidemia-as key contributors to the pathogenesis and progression of PCOS. Emerging interventions targeting these metabolic disturbances, including caloric restriction, GLP-1-based therapies, and bariatric surgery, have shown efficacy in alleviating PCOS symptoms and potentially blocking their inheritance.
View Article and Find Full Text PDFEur J Prev Cardiol
September 2025
Institute of Clinical Chemistry, University and University Hospital of Zurich, Zurich, Switzerland.
Aims: Bariatric surgery (BS) reduces obesity-associated systemic inflammation leading to multiple cardiovascular (CV) and metabolic benefits. Here, we tested whether measuring vaso-inflammatory cytokines, gut hormones, and circulating extracellular vesicles (EV) provide vaso-inflammatory-metabolic signatures that better correlate to CV-metabolic outcomes after BS, compared to a standard clinical assessment including body weight (BW) loss and traditional CV risk factors.
Methods: In 111 patients with severe obesity, conventional clinical-biochemical parameters and non-conventional vaso-inflammatory-metabolic markers were analyzed at baseline, after 1- (T12) and 3-years (T36) post-BS and were associated to post-surgical BW loss and improvement of patients' CV-metabolic profile.